Research peptide vendor
A six-product research-peptide shop whose FAQ discusses certificates of analysis at length without providing a single one. Independent testing by Finnrick records 63 tests across seven compounds with eleven failures and a 67% composite rating, placing it 342nd of 489 ranked vendors.
quality claims we could confirm ourselves, rather than repeat from the vendor's marketing.
Exclusive code
15% OFF
Use ATLAS15 at checkout for 15% off any BioLongevity Labs order. First order or repeat.
15% OFF at BioLongevity Labs
KLOW and GLOW blends, NAD+, and the GLP analogues sold as Tirz, Reta and Cagrilin.
Sold as research materials, with no approval for human or veterinary use. The site says research products aren't intended for personal use. Nothing here is medical advice, and the independent test record below is the part worth reading before anything else.
Graded by whether we could confirm it ourselves or are only repeating what the vendor states. A vendor's honesty about its own testing is a different question from what a published trial shows, so this is a separate scale from the evidence grades on our guides.
The catalogue page reads showing all 6 results: Cagrilin at $64.99, GLOW at $99.99, KLOW at $199.99, NAD+ at $84.99, Reta from $44.99 to $239.99, and Tirz. Prices are visible without an account. A banner offers free shipping over $500 and 15% off for crypto payment under the code I47XZTSP.
Where the vendor states thisWe couldn't find one. There's no test results page in the navigation, no certificate PDF linked from any product page we opened, and no document anywhere on the site. The FAQ has a whole Laboratory Documentation section answering what a certificate of analysis is and whether one batch verifies every batch, without ever linking one. Product copy defers to any documentation actually supplied and to the applicable product label and batch documentation. The phrasing is careful; the documents are absent.
Where the vendor states thisFinnrick, which publishes independent peptide assays, lists 63 tests of Inno Peptides material across seven compounds: 51 passes, 11 failures and one incomplete, with a composite rating of 67% and a rank of 342nd of 489 ranked vendors. Per compound it scores GHK-Cu 90%, retatrutide 81%, tirzepatide 80%, BPC-157 62%, cagrilintide 60%, tesamorelin 46% and MOTS-c 37%. The most recent entry, a retatrutide test dated 21 October 2026, is a fail. This is third-party data we didn't generate. We haven't audited Finnrick's laboratories, and its underlying PDFs sit behind a paid tier.
Where the vendor states thisIts published analysis reads that purity results on the stronger compounds run 99.6 to 99.9%, while retatrutide and tirzepatide include sizable low fills and missing batch IDs. In plain terms: the material tends to be what it says it is, and there tends to be less of it in the vial than the label states. Missing batch identifiers on an independent test match the absence of any lot documentation on the site itself.
Where the vendor states thisThe site states no address, no jurisdiction and no shipping origin. Finnrick's vendor record lists nine contact channels, five of them WhatsApp numbers on Hong Kong and US codes, plus a separate innopeptide.com domain and a Spanish-language subdomain, and it ties the operation to a Wuhan chemical-export network. We couldn't confirm that attribution ourselves, so we're reporting it as a third party's published claim rather than as our own finding.
Where the vendor states thisIt isn't, on the one product that compares directly. Inno Peptides sells a KLOW blend at 74mg for $199.99. Pacific Edge Labs sells KLOW at 80mg for $118.95. More of the same blend for forty percent less money, from a vendor that publishes lot-numbered certificates.
Where the vendor states thisThis is the central problem. A shop that writes a Laboratory Documentation FAQ and publishes no laboratory documentation has described the standard it doesn't meet. Every mention defers to documentation actually supplied, batch documentation or the applicable product label, none of which is on the website. Compare Pacific Edge Labs, which publishes around 75 lot-numbered reports.
Finnrick records 63 tests, 51 passes and 11 failures, with the latest entry on 21 October 2026 failing. Its per-compound scores fall to 37% for MOTS-c and 46% for tesamorelin. Those are two of the compounds this market buys most readily on trust alone.
Finnrick's analysis points at sizable low fills on retatrutide and tirzepatide. That's the failure mode that's hardest for a buyer to notice: the powder tests as the right compound at high purity, so a certificate would read well, while the vial contains less than the label says. Dosing from the stated figure would then under-deliver by an unknown margin.
The site names no jurisdiction or shipping origin. Finnrick lists five WhatsApp numbers, a second domain and a Spanish subdomain against this vendor, and describes continuing direct-message sales. A shop that sells through chat apps under several domains is harder to hold to anything, a refund policy included.
Crypto incentives aren't inherently a problem, and plenty of legitimate vendors offer them because card processors avoid this category. What they do remove is your recourse. A card payment can be disputed; a crypto payment cannot, and that matters more when the vendor publishes no documentation and no address.
Plenty of peptide vendors publish nothing about testing. This one publishes a section on it.
The FAQ carries a Laboratory Documentation heading with three questions under it: what a certificate of analysis is, whether a certificate for one batch verifies every batch, and what to check when reviewing a laboratory report. Those are the right questions, and the third one is a question most vendors would rather you did not ask.
There is no certificate behind any of it. No test results page in the navigation, no PDF on a product listing, nothing in the footer. Product copy sends you to any documentation actually supplied and to the applicable product label and batch documentation, both of which sit somewhere other than the website.
We're reluctant to read intent into copy. What we can say is that the site shows it knows what the standard is, which rules out the kindest explanation for not meeting it.
Finnrick's reading of its own data is the most useful thing on this page, because it describes a failure that looks fine on paper.
Its analysis records purity of 99.6 to 99.9% on the stronger compounds alongside sizable low fills and missing batch IDs on retatrutide and tirzepatide. The compound is right and the amount is short, so a purity assay would pass. A certificate showing 99.8% purity would be accurate, and it would tell you nothing about the problem.
That's why quantity testing matters separately from identity and purity, a distinction Pacific Edge Labs makes explicitly in its own FAQ: purity, quantity and identity results answer different questions.
If you're dosing from a label figure on a vial that holds less than it claims, every calculation downstream is wrong by a margin nobody has measured. Our peptide calculator assumes the vial contains what the label says, and that's an assumption worth checking.
The two blends are the clearest comparison, because they are the same formulas under the same names.
KLOW at Inno Peptides is $199.99 for 74mg. At Pacific Edge Labs it is $118.95 for 80mg, with lot KLOW016 in an open certificate library. GLOW is $99.99 here against $114.95 there for 70mg, so that one is closer, and the deciding factor is the documentation rather than the price.
For the GLP analogues, the low-fill finding is the reason to look elsewhere regardless of price, since that is the specific compound class Finnrick flagged. Our brands index ranks every vendor we have checked on the same five-point standard.
Before you go
15% OFF
Don't check out without it. Use ATLAS15 at checkout for 15% off any BioLongevity Labs order. First order or repeat.
It's a real shop that takes real orders, and that's about as far as we can go. It publishes no certificate of analysis anywhere, states no address or shipping origin, and independent testing by Finnrick records 11 failures across 63 tests with a 67% composite rating. We would buy the same blends elsewhere.
Every fact above traces to one of these pages, published by the vendor itself and checked on October 26, 2026. Vendor policy pages change without notice, so if something here looks out of date, it probably is.
Compare against
Open pricing, public COAs, strict research-only gate
